Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tianasen in GNAO1-Encephalopathy
NCT07363603Phase 2Recruiting
- Sponsor
- Pirogov Russian National Research Medical University
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of tianasen in developmental and epileptic encephalopathy 17 (DEE17), epilepsy, hyperkinesia, sponsored by Pirogov Russian National Research Medical University. Started Sep 2025; status: recruiting.
02
Drugs
tianasen
03
Conditions
developmental and epileptic encephalopathy 17 (DEE17)epilepsyhyperkinesia
Beyond the preview
Go deeper on NCT07363603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363603.